No­var­tis punts a late-stage PI3K drug with a wor­ry­ing safe­ty pro­file to one of Chi­na’s up­start biotechs

Just months af­ter a group of re­searchers warned against the fur­ther de­vel­op­ment of a wor­ry­ing PI3K in­hibitor project No­var­tis had been work­ing on, the phar­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER